Clinical trial
Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and…
NCT00050986 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00050986 |
|---|---|
| Title | Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme |
| Official title | Phase I/II Evaluation Temozolomide and Farnesyl Transferase Inhibitor ZARNESTRA (R115777) for the Treatment of Recurrent and Progressive Glioblastoma Multiforme |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Johnson & Johnson Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme |
| Intervention type | Drug |
| Interventions | Temozolomide, R115777 |
| Enrollment | 55 |
| Start date | Dec 1, 2002 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jan 3, 2003 |
| Last update posted | Sep 22, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: